The estimated Net Worth of Mary Anne Heino is at least $80.4 Milione dollars as of 2 August 2024. Ms. Heino owns over 10,481 units of Lantheus Inc stock worth over $46,379,400 and over the last 9 years she sold LNTH stock worth over $29,728,065. In addition, she makes $4,320,910 as President, Chief Executive Officer e Director at Lantheus Inc.
Mary has made over 35 trades of the Lantheus Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently she sold 10,481 units of LNTH stock worth $1,000,936 on 2 August 2024.
The largest trade she's ever made was selling 94,244 units of Lantheus Inc stock on 2 March 2023 worth over $6,882,639. On average, Mary trades about 14,591 units every 50 days since 2015. As of 2 August 2024 she still owns at least 454,923 units of Lantheus Inc stock.
You can see the complete history of Ms. Heino stock trades at the bottom of the page.
Mary Anne Heino serves as President, Chief Executive Officer, Director of the Company. She previously served as our Chief Operating Officer, a position she held from March 2015 until August 2015, and as our Chief Commercial Officer, a position she held from April 2013 (when she joined the Company) until March 2015. Ms. Heino brings 30 years of diverse pharmaceutical industry experience to the Board. Prior to joining Lantheus, Ms. Heino led Angelini Labopharm LLC and Labopharm USA in the roles of President and Senior Vice President of World Wide Sales and Marketing from February 2007 to March 2012. From May 2000 until February 2007, Ms. Heino served in numerous capacities at Centocor, Inc., a Johnson & Johnson (“J&J”) company. Ms. Heino began her professional career with Janssen Pharmaceutica, another J&J company, in June 1989 and worked her way up to the role of Field Sales Director in 1999. Ms. Heino received her Master in Business Administration from the Stern School of Business at New York University. She earned a Bachelor of Science in Nursing from the City University of New York and a Bachelor of Science in Biology from the State University of New York at Stony Brook. Ms. Heino currently serves on the Executive Committee of the Massachusetts Business Roundtable and the Board of MassMEDIC. Ms. Heino was chosen as a Director because of her role as President and Chief Executive Officer, which gives her an extensive understanding of our business and operations, and because of her strong commercial experience in the pharmaceutical industry.
As the President, Chief Executive Officer e Director of Lantheus Inc, the total compensation of Mary Heino at Lantheus Inc is $4,320,910. There are no executives at Lantheus Inc getting paid more.
Mary Heino is 60, she's been the President, Chief Executive Officer e Director of Lantheus Inc since 2015. There are 5 older and 19 younger executives at Lantheus Inc. The oldest executive at Lantheus Holdings Inc is James Thrall, 76, who is the Independent Director.
Mary's mailing address filed with the SEC is C/O LANTHEUS HOLDINGS, INC., 201 BURLINGTON ROAD, SOUTH BLDG, BEDFORD, MA, 01730.
Over the last 9 years, insiders at Lantheus Inc have traded over $500,725,766 worth of Lantheus Inc stock and bought 8,000 units worth $141,200 . The most active insiders traders include David F Burgstahler, Capital Partners Gp, Llc Av... e Sriram Venkataraman. On average, Lantheus Inc executives and independent directors trade stock every 11 days with the average trade being worth of $15,777,680. The most recent stock trade was executed by James H Thrall on 21 August 2024, trading 1,000 units of LNTH stock currently worth $98,520.
lantheus holdings, inc. (nasdaq: lnth) is the parent company of lantheus medical imaging, inc. (lmi), which is a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. lmi provides a broad portfolio of products, which are primarily used for the diagnosis of cardiovascular diseases. lmi’s key products include the echocardiography contrast agent definity® vial for (perflutren lipid microsphere) injectable suspension; technelite® (technetium tc99m generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and xenon (xenon xe 133 gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. the company is headquartered in north billerica, massachusetts with offices in puerto rico and canada. for more information, visit www.lantheus.com.
Lantheus Inc executives and other stock owners filed with the SEC include: